Dr Jacqueline Garcia speaks to ecancer at virtual ASH 2020 about the phase I study she presented on the safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS/AML in the post-BMT or transplant naïve settings.
She begins by explaining the rationale of the study before detailing the methods used.
Dr Garcia reports that decitabine plus ipilimumab showed encouraging clinical activity with an expected adverse events profile.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.